Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use. Surveyed primary care physicians say that a therapy's effect on overall irritable bowel syndrome symptoms is the attribute that most influences their prescribing decisions in non-constipation predominant irritable bowel syndrome.
The new report entitled Irritable Bowel Syndrome: A New Therapy for Non-Constipation-Predominant IBS with Greatly Improved Efficacy Will Reach Near-Blockbuster Status also finds that both Lotronex and Tioga/Ono's asimadoline will earn Decision Resources' clinical gold standard status for non-constipation predominant irritable bowel syndrome for 2013 and 2018, following the launch of asimadoline in 2013.
"Lotronex is currently Decision Resources' clinical gold standard for the treatment of non-constipation predominant irritable bowel syndrome because it has better efficacy than other current therapies, particularly on treating overall symptoms -- the attribute that most influences prescribing physicians," said Decision Resources Analyst Dancella Fernandes, M.B.A., Ph.D. "Although only in early clinical trials, asimadoline will share the clinical gold standard status once it is available in 2013 based on available clinical data and thought leader opinion, and will likely garner a greater patient share than Lotronex following its launch."
Feeling lonely? It may affect how your brain reacts to food, new research suggests